STAT2d
Lilly expands its Zepbound vial offering, as Hims pulls back on semaglutide
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout newsletter.
Construction Dive12h
Eli Lilly expands US manufacturing build-out with $50B target
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...
Eli Lilly announces $27-billion US expansion: To add 13,000 jobs and new manufacturing sites
Eli Lilly & Co has announced a $27-billion expansion of its US manufacturing operations, adding four new sites and creating ...
Eli Lilly and Company (LLY): A High Growth Mega Cap Stock You Can Buy and Hold for the Next 5 Years
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
24/7 Wall St. on MSN3d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
FiercePharma3d
Lilly banks stockpile of oral GLP-1 drug with potential launch still more than a year away
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Lilly to Spend $27 Billion to Bolster US Drug Manufacturing
Eli Lilly & Co. will spend at least $27 billion to build four US manufacturing plants, the latest company to brace for the ...